📰 Cameron Radinovic News
Cameron Radinovic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Cameron Radinovic. Real-time updates on events, politics, business and more.
April 24, 2024
NEW YORK, April 24, 2024 -- Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders,...
February 27, 2024
NEW YORK, Feb. 27, 2024 -- Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, today...
February 8, 2024
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the developmen...
December 5, 2023
Company presents positive results of a pre-specified patient population in Study 403 examining the effects of CAPLYTA® (lumateperone) in patients experiencing a major depressive episode with anxious distress and mixed
November 15, 2023
NEW YORK, Nov. 15, 2023 -- Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, today...
October 31, 2023
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and...
September 20, 2023
NEW YORK, Sept. 20, 2023 -- Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders,...
September 11, 2023
NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders,
August 13, 2023
Operator: Good morning and thank you for your participation. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session.
May 4, 2023
04.05.2023 - Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023 net product sales were $94.7 million, compared to $34.8 million for the same period in 2022, representing a 173% increase Q1 2023 CAPLYTA ...